103 related articles for article (PubMed ID: 15031284)
21. Pathway complexity of prion protein assembly into amyloid.
Baskakov IV; Legname G; Baldwin MA; Prusiner SB; Cohen FE
J Biol Chem; 2002 Jun; 277(24):21140-8. PubMed ID: 11912192
[TBL] [Abstract][Full Text] [Related]
22. Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation.
Glaves JP; Ladner-Keay CL; Bjorndahl TC; Wishart DS; Sykes BD
Biochim Biophys Acta Proteins Proteom; 2018 Sep; 1866(9):982-988. PubMed ID: 29935976
[TBL] [Abstract][Full Text] [Related]
23. Cell Biology of Prion Protein.
Sarnataro D; Pepe A; Zurzolo C
Prog Mol Biol Transl Sci; 2017; 150():57-82. PubMed ID: 28838675
[TBL] [Abstract][Full Text] [Related]
24. A role for His155 in binding of human prion peptide144-167 to immobilised prion protein.
Hesp JR; Raven ND; Sutton JM
Biochem Biophys Res Commun; 2007 Oct; 362(3):695-9. PubMed ID: 17761148
[TBL] [Abstract][Full Text] [Related]
25. Aggregation and fibrillization of prions in lipid membranes.
Kazlauskaite J; Pinheiro TJ
Biochem Soc Symp; 2005; (72):211-22. PubMed ID: 15649144
[TBL] [Abstract][Full Text] [Related]
26. Prion protein-related proteins from zebrafish are complex glycosylated and contain a glycosylphosphatidylinositol anchor.
Miesbauer M; Bamme T; Riemer C; Oidtmann B; Winklhofer KF; Baier M; Tatzelt J
Biochem Biophys Res Commun; 2006 Mar; 341(1):218-24. PubMed ID: 16414019
[TBL] [Abstract][Full Text] [Related]
27. The role of prion peptide structure and aggregation in toxicity and membrane binding.
Rymer DL; Good TA
J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
[TBL] [Abstract][Full Text] [Related]
28. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity.
Salmona M; Forloni G; Diomede L; Algeri M; De Gioia L; Angeretti N; Giaccone G; Tagliavini F; Bugiani O
Neurobiol Dis; 1997; 4(1):47-57. PubMed ID: 9258911
[TBL] [Abstract][Full Text] [Related]
29. Structural dependence of the cellular isoform of prion protein on solvent: spectroscopic characterization of an intermediate conformation.
Pergami P; Bramanti E; Ascoli GA
Biochem Biophys Res Commun; 1999 Nov; 264(3):972-8. PubMed ID: 10544040
[TBL] [Abstract][Full Text] [Related]
30. PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.
Marshall KE; Hughson A; Vascellari S; Priola SA; Sakudo A; Onodera T; Baron GS
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847358
[TBL] [Abstract][Full Text] [Related]
31. Functionally relevant domains of the prion protein identified in vivo.
Baumann F; Pahnke J; Radovanovic I; Rülicke T; Bremer J; Tolnay M; Aguzzi A
PLoS One; 2009 Sep; 4(9):e6707. PubMed ID: 19738901
[TBL] [Abstract][Full Text] [Related]
32. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process.
Lee S; Eisenberg D
Nat Struct Biol; 2003 Sep; 10(9):725-30. PubMed ID: 12897768
[TBL] [Abstract][Full Text] [Related]
33. Membrane interactions and conformational preferences of human and avian prion N-terminal tandem repeats: the role of copper(II) ions, pH, and membrane mimicking environments.
Di Natale G; Pappalardo G; Milardi D; Sciacca MF; Attanasio F; La Mendola D; Rizzarelli E
J Phys Chem B; 2010 Nov; 114(43):13830-8. PubMed ID: 20936829
[TBL] [Abstract][Full Text] [Related]
34. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
[TBL] [Abstract][Full Text] [Related]
35. In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate.
Faburay B; Tark D; Kanthasamy AG; Richt JA
Prion; 2014; 8(6):393-403. PubMed ID: 25495764
[TBL] [Abstract][Full Text] [Related]
36. Binding of prion protein to lipid membranes and implications for prion conversion.
Sanghera N; Pinheiro TJ
J Mol Biol; 2002 Feb; 315(5):1241-56. PubMed ID: 11827491
[TBL] [Abstract][Full Text] [Related]
37. Studies on the putative interactions between the organophosphorus insecticide Phosmet and recombinant mouse PrP and its implication in the BSE epidemic.
Shaw I; Berry C; Lane E; Fitzmaurice P; Clarke D; Holden A
Vet Res Commun; 2002 Jun; 26(4):263-71. PubMed ID: 12184497
[TBL] [Abstract][Full Text] [Related]
38. The effect of disease-associated mutations on the folding pathway of human prion protein.
Apetri AC; Surewicz K; Surewicz WK
J Biol Chem; 2004 Apr; 279(17):18008-14. PubMed ID: 14761942
[TBL] [Abstract][Full Text] [Related]
39. Folding and intrinsic stability of deletion variants of PrP(121-231), the folded C-terminal domain of the prion protein.
Eberl H; Glockshuber R
Biophys Chem; 2002 May; 96(2-3):293-303. PubMed ID: 12034448
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity.
Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T
OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
